Skip to main content

Advertisement

Open Peer Review Reports for: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
19 Mar 2018 Submitted Original manuscript
21 Apr 2018 Author responded Author comments - Rui-Lian Chen
Resubmission - Version 2
21 Apr 2018 Submitted Manuscript version 2
30 Jul 2018 Reviewed Reviewer Report - Junling Li
16 Aug 2018 Reviewed Reviewer Report - Reviewer 2
16 Sep 2018 Author responded Author comments - Rui-Lian Chen
Resubmission - Version 3
16 Sep 2018 Submitted Manuscript version 3
24 Sep 2018 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
12 Nov 2018 Editorially accepted
26 Nov 2018 Article published 10.1186/s12885-018-5078-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement